In recent trading session, Abbott Laboratories (NYSE:ABT) saw 1.45 million shares changing hands at last check today with its beta currently measuring 0.72. Company’s recent per share price level of $132.01 trading at $3.45 or 2.68% at last check today assigns it a market valuation of $229.68B. That most recent trading price of ABT’s stock is at a discount of -6.98% from its 52-week high price of $141.23 and is indicating a premium of 24.47% from its 52-week low price of $99.71. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.21 million shares which gives us an average trading volume of 7.17 million if we extend that period to 3-months.
For Abbott Laboratories (ABT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.93. Splitting up the data highlights that, out of 13 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 12 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Abbott Laboratories (NYSE:ABT) trade information
Upright in the green today for gaining 2.68%, in the last five days ABT remained trading in the red while hitting it’s week-highest on Friday, 05/09/25 when the stock touched $132.01 price level, adding 2.19% to its value on the day. Abbott Laboratories’s shares saw a change of 16.71% in year-to-date performance and have moved -1.49% in past 5-day. Abbott Laboratories (NYSE:ABT) showed a performance of 4.59% in past 30-days. Number of shares sold short was 21.12 million shares which calculate 2.69 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 137.5 to the stock, which implies a rise of 3.99% to its recent value today. Analysts have been projecting 135 as a low price target for the stock while placing it at a high target of 140. It follows that stock’s current price would drop -2.26% in reaching the projected high whereas dropping to the targeted low would mean a loss of -2.26% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 29.98% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 10.44% while estimates for its earnings growth in next 5 years are of 10.34%.
ABT Dividends
Abbott Laboratories is more likely to be releasing its next quarterly report on 2025-Apr-15 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 1.73%, the share has a forward dividend of 2.28 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 1.67%.
Abbott Laboratories (NYSE:ABT)’s Major holders
Insiders are in possession of 0.54% of company’s total shares while institution are holding 80.39 percent of that, with stock having share float percentage of 80.83%. Investors also watch the number of corporate investors in a company very closely, which is 80.39% institutions for Abbott Laboratories that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at ABT for having 166.35 million shares of worth $17.29 billion. And as of 2024-06-30, it was holding 9.5932 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 131.13 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.5619 of outstanding shares, having a total worth of $13.63 billion.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 54.34 shares of worth $7.19 billion or 3.12% of the total outstanding shares. The later fund manager was in possession of 46.95 shares on Dec 31, 2024 , making its stake of worth around $6.21 billion in the company or a holder of 2.70% of company’s stock.
